Investigation of The Relationship Between COVID-19 Severity and Serum Adropin Levels

Cihad Özçelik; Hamza Halıcı; İbrahim Hakkı Tör; Sevgi Karabulut Uzunçakmak; Pelin Aydın

Makale detayları

Investigation of The Relationship Between COVID-19 Severity and Serum Adropin Levels

Yazarlar:

Cihad Özçelik | Hamza Halıcı | İbrahim Hakkı Tör | Sevgi Karabulut Uzunçakmak | Pelin Aydın

Yayıncı:

Ataturk University

Ana Başlıklar:

Tıbbi Farmakoloji | Anesteziyoloji

Dergi:

Current Research in Health Sciences Vol.1 Issue 1, pp.15-20

Belge Tipi:

Makale

Yayın Tarihi:

2/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001312570

pISSN:

3023-6991

Anahtar kelimeler:

Özet:

 Abstract Aim: COVID-19 is a multisystemic disease with high mortality and morbidity. It is very important to understand the pathogenesis of the disease and to develop pharmacological treatment methods. The aim of this study was to measure serum adropin levels in COVID-19 patients in the ward and intensive care unit and to investigate whether this value can be a prognostic factor or a pharmacological treatment target. Materials and Methods: 116 volunteer participants were included in the study. Participants were grouped as the control group consisting of patients without any disease, patients diagnosed with COVID-19 and hospitalised in the ward, patients diagnosed with COVID-19 and hospitalised in Level 2 intensive care and patients diagnosed with COVID-19 and hospitalised in Level 3 intensive care. Venous blood was taken from the patients. Serum adropin levels were measured according to the manufacturers instructions. ROC analysis was also performed. Results: According to serum adropin measurements, serum adropin levels of patients with COVID-19 who were hospitalised in the ward decreased compared to the control group.p0.05. In Level 2 intensive care and Level 3 intensive care patients, serum adropin levels decreased compared to patients in the ward.p0.05 According to Roc analysis, 333.1 ngL adropin had a specificity of 0.8167 95, 0.6956-0.9048 and a sensitivity of 0.6522 95, 0.4273-0.8362. Conclusion: COVID-19 is a disease with high mortality and morbidity affecting all systems. With this study, we think that serum adropin levels may be a prognostic factor or a new pharmacological treatment target and may shed light on new studies.

 Abstract Aim: COVID-19 is a multisystemic disease with high mortality and morbidity. It is very important to understand the pathogenesis of the disease and to develop pharmacological treatment methods. The aim of this study was to measure serum adropin levels in COVID-19 patients in the ward and intensive care unit and to investigate whether this value can be a prognostic factor or a pharmacological treatment target. Materials and Methods: 116 volunteer participants were included in the study. Participants were grouped as the control group consisting of patients without any disease, patients diagnosed with COVID-19 and hospitalised in the ward, patients diagnosed with COVID-19 and hospitalised in Level 2 intensive care and patients diagnosed with COVID-19 and hospitalised in Level 3 intensive care. Venous blood was taken from the patients. Serum adropin levels were measured according to the manufacturers instructions. ROC analysis was also performed. Results: According to serum adropin measurements, serum adropin levels of patients with COVID-19 who were hospitalised in the ward decreased compared to the control group.p0.05. In Level 2 intensive care and Level 3 intensive care patients, serum adropin levels decreased compared to patients in the ward.p0.05 According to Roc analysis, 333.1 ngL adropin had a specificity of 0.8167 95, 0.6956-0.9048 and a sensitivity of 0.6522 95, 0.4273-0.8362. Conclusion: COVID-19 is a disease with high mortality and morbidity affecting all systems. With this study, we think that serum adropin levels may be a prognostic factor or a new pharmacological treatment target and may shed light on new studies.

 Abstract Aim: COVID-19 is a multisystemic disease with high mortality and morbidity. It is very important to understand the pathogenesis of the disease and to develop pharmacological treatment methods. The aim of this study was to measure serum adropin levels in COVID-19 patients in the ward and intensive care unit and to investigate whether this value can be a prognostic factor or a pharmacological treatment target. Materials and Methods: 116 volunteer participants were included in the study. Participants were grouped as the control group consisting of patients without any disease, patients diagnosed with COVID-19 and hospitalised in the ward, patients diagnosed with COVID-19 and hospitalised in Level 2 intensive care and patients diagnosed with COVID-19 and hospitalised in Level 3 intensive care. Venous blood was taken from the patients. Serum adropin levels were measured according to the manufacturers instructions. ROC analysis was also performed. Results: According to serum adropin measurements, serum adropin levels of patients with COVID-19 who were hospitalised in the ward decreased compared to the control group.p0.05. In Level 2 intensive care and Level 3 intensive care patients, serum adropin levels decreased compared to patients in the ward.p0.05 According to Roc analysis, 333.1 ngL adropin had a specificity of 0.8167 95, 0.6956-0.9048 and a sensitivity of 0.6522 95, 0.4273-0.8362. Conclusion: COVID-19 is a disease with high mortality and morbidity affecting all systems. With this study, we think that serum adropin levels may be a prognostic factor or a new pharmacological treatment target and may shed light on new studies.

 Abstract Aim: COVID-19 is a multisystemic disease with high mortality and morbidity. It is very important to understand the pathogenesis of the disease and to develop pharmacological treatment methods. The aim of this study was to measure serum adropin levels in COVID-19 patients in the ward and intensive care unit and to investigate whether this value can be a prognostic factor or a pharmacological treatment target. Materials and Methods: 116 volunteer participants were included in the study. Participants were grouped as the control group consisting of patients without any disease, patients diagnosed with COVID-19 and hospitalised in the ward, patients diagnosed with COVID-19 and hospitalised in Level 2 intensive care and patients diagnosed with COVID-19 and hospitalised in Level 3 intensive care. Venous blood was taken from the patients. Serum adropin levels were measured according to the manufacturers instructions. ROC analysis was also performed. Results: According to serum adropin measurements, serum adropin levels of patients with COVID-19 who were hospitalised in the ward decreased compared to the control group.p0.05. In Level 2 intensive care and Level 3 intensive care patients, serum adropin levels decreased compared to patients in the ward.p0.05 According to Roc analysis, 333.1 ngL adropin had a specificity of 0.8167 95, 0.6956-0.9048 and a sensitivity of 0.6522 95, 0.4273-0.8362. Conclusion: COVID-19 is a disease with high mortality and morbidity affecting all systems. With this study, we think that serum adropin levels may be a prognostic factor or a new pharmacological treatment target and may shed light on new studies.

Makale detayları

Investigation of The Relationship Between COVID-19 Severity and Serum Adropin Levels

Yazarlar:

Cihad Özçelik | Hamza Halıcı | İbrahim Hakkı Tör | Sevgi Karabulut Uzunçakmak | Pelin Aydın

Yayıncı:

Ataturk University

Ana Başlıklar:

Tıbbi Farmakoloji | Anesteziyoloji

Dergi:

Current Research in Health Sciences Vol.1 Issue 1, pp.15-20

Belge Tipi:

Makale

Yayın Tarihi:

2/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001312570

pISSN:

3023-6991

COVID-19

SARS CoV-2

Endothel

Adropin

ıntensive care unit

Sayı

Makale detayları

Investigation of The Relationship Between COVID-19 Severity and Serum Adropin Levels

Yazarlar: Cihad Özçelik | Hamza Halıcı | İbrahim Hakkı Tör | Sevgi Karabulut Uzunçakmak | Pelin Aydın

Yayıncı: Ataturk University

Ana Başlıklar: Tıbbi Farmakoloji | Anesteziyoloji

Dergi: Current Research in Health Sciences Vol.1 Issue 1, pp.15-20

Belge Tipi: Makale

Yayın Tarihi: 2/2024

Belge Dili: İngilizce

Document ID (Org No.): 2001312570

pISSN: 3023-6991

COVID-19

SARS CoV-2

Endothel

Adropin

ıntensive care unit

Sayı

Yazarlar:

Cihad Özçelik | Hamza Halıcı | İbrahim Hakkı Tör | Sevgi Karabulut Uzunçakmak | Pelin Aydın

Yayıncı:

Ataturk University

Ana Başlıklar:

Tıbbi Farmakoloji | Anesteziyoloji

Dergi:

Current Research in Health Sciences Vol.1 Issue 1, pp.15-20

Belge Tipi:

Makale

Yayın Tarihi:

2/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001312570

pISSN:

3023-6991